Table 2.
Clinicopathological characteristics of the entire cohort of 41 patients with ESCC.
| Characters | Radiosensitive | Radioresistant | Total | p |
|---|---|---|---|---|
| Gender | 0.706 | |||
| Male | 17 | 15 | 32 | |
| Female | 6 | 3 | 9 | |
| Age (range) | 61 (47-70) | 63 (47-70) | 61 (47-70) | 0.406 |
| ECOG score | 0.767 | |||
| 0 | 13 | 11 | 24 | |
| 1 | 10 | 7 | 17 | |
| Tumor location | 0.515 | |||
| Cervical | 4 | 3 | 7 | |
| Upper | 5 | 6 | 11 | |
| Middle | 11 | 8 | 19 | |
| Lower | 3 | 1 | 4 | |
| T stage | 0.112 | |||
| 2 | 1 | 1 | 2 | |
| 3 | 11 | 3 | 14 | |
| 4 | 11 | 14 | 25 | |
| N stage | 0.164 | |||
| 0 | 2 | 0 | 2 | |
| 1 | 14 | 8 | 22 | |
| 2 | 7 | 10 | 17 | |
| M stage a | 0.542 | |||
| 0 | 20 | 15 | 35 | |
| 1 | 3 | 3 | 6 | |
| Clinical stage b | 0.112 | |||
| II | 1 | 1 | 2 | |
| III | 11 | 3 | 14 | |
| IV | 11 | 14 | 25 | |
| GTV (cGy, range) | 6000 (4000–6600) | 6000 (5040–6600) | 6000 (4000–6600) | 0.128 |
| CTV (cGy, range) | 5040 (4000–5040) | 5040 (4500–5040) | 5040 (4000–5040) | 0.300 |
| IC | 0.574 | |||
| None | 7 | 8 | 15 | |
| PF | 5 | 2 | 7 | |
| TL | 1 | 0 | 1 | |
| TP | 10 | 8 | 18 |
There were no significant differences between radiosensitive and radioresistant patients regarding the distributions of gender, age, ECOG score, tumor location and clinical stage. ECOG, eastern cooperative oncology group; GTV, gross tumor volume; CTV, clinical target volume; PF, platinum plus fluorouracil; TP, platinum plus taxane; a, M1 means Supraclavicular lymphatic node metastasis; IC, Induction chemotherapy; b, according to the 7th AJCC TNM staging system.